Why My Price Target for Valeant Pharmaceuticals Intl Inc. Is $0

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) should not be bought at any price.

| More on:
The Motley Fool

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) reported unaudited results for the fourth quarter of 2015, and they were ugly to say the least. We’ll take a closer look at the numbers and also look at why the stock shouldn’t be bought at any price.

Very disappointing numbers

If there was any good news, it’s that Valeant generated US$2.8 billion during the fourth quarter. Otherwise, there is nothing positive to report.

Valeant’s Q4 earnings per share (EPS) came in at US$2.50, which was US$0.11 below consensus estimates. But the real bad news came when the company gave its updated guidance. For the year 2016, Valeant expects revenue between US$11 billion and US$11.2 billion, down from prior guidance of US$12.5-12.7 billion. EPS is expected to come in at US$9.50-10.50, again, down from prior guidance, which was US$13.25-13.75.

Even more worryingly, Valeant forecasted US$6.2-6.6 billion in adjusted EBITDA in the 12 months following March 31, but then lowered that estimate to US$6 billion during the earnings call. Management blamed the error on a “typo,” but it’s another sign that they don’t have a handle on their own business.

More trouble from here

Ever since Valeant’s relationship with Philidor was exposed, the company has found itself under increased scrutiny, and that seems to have affected the rest of its business. In the press release, Valeant noted that business slowed in a number of areas, even ones that weren’t a big part of Philidor. For example, Valeant’s gastrointestinal business experienced softer-than-expected sales in the fourth quarter.

This scrutiny will only grow more intense. Politicians are angry about Valeant’s high drug prices. Investigations from the SEC and other public bodies are ongoing. And we still haven’t gotten to the bottom of what was going on at Philidor.

A default could be looming

Valeant’s biggest problem now is its balance sheet. The company has over US$30 billion of debt on its books and has plans to pay down US$1.7 billion this year. But the efforts may not be enough.

If Valeant does not submit its annual report by Thursday, it will breach the covenants on its bonds, paving the way for a default. From there, the company will have a 60-day window to make the proper filings and avoid defaulting.

Here’s the problem though: after the latest numbers came in lower than expected, Valeant may have already breached one of its debt covenants. And that may be why the company has yet to release audited results. To be fair, that is just speculation at this point. But Valeant has also said it intends to enter into negotiations with its creditors regarding covenants.

This is why Valeant’s shares could easily reach $0, and I wouldn’t recommend buying the shares at any price. Put another way, this story is nowhere near over.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Benjamin Sinclair has no position in any stocks mentioned.  Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

Dividend Stocks

Enbridge Stock: This Dividend Aristocrat Looks Like a Steal in 2023

Here are some key factors that make ENB a great Canadian dividend stock to buy on the dip in 2023.

Read more »

Stocks for Beginners

Invest in These Stocks to Make the Most of Your TFSA

If you are unable to find fundamentally strong stocks for your TFSA in 2023, here are two great stock picks…

Read more »

A red umbrella stands higher than a crowd of black umbrellas.
Dividend Stocks

U.S. Debt Ceiling: Is It Safe to Invest Right Now?

The U.S. debt ceiling is in the headlines again. You can play it safe by investing long term in wonderful…

Read more »

Stocks for Beginners

2 TSX Stocks to Smooth Over the Market’s Bumps

Here are two of the safest TSX stocks you can buy in June 2023 without worrying about high stock market…

Read more »

Dice engraved with the words buy and sell
Bank Stocks

1 Bank Stock I’d Buy Today (and 1 I’d Sell)

Bank earnings season is upon us, and I’d look to buy Bank of Nova Scotia (TSX:BNS) while avoiding another top…

Read more »

Credit card, online shopping, retail
Tech Stocks

Should You Buy Lightspeed Stock After Its Q4 Earnings?

Despite its volatility, I expect Lightspeed to outperform in the long run due to its healthy growth prospects and cheaper…

Read more »

oil and natural gas
Energy Stocks

These Canadian Energy Stocks Are Bargain Buys for 2023

Here are two of the best Canadian energy stocks you can buy on the dip in 2023 to hold for…

Read more »

A worker drinks out of a mug in an office.
Bank Stocks

Royal Bank Stock Pays a 4.37% Dividend Yield, But Another Stock Looks Even Better Today

Royal Bank of Canada (TSX:RY) may be the top dog on the TSX, but I prefer another dividend stock for…

Read more »